At a glance
ClinicalIndex Comparison RecordN/ACompleted· 106 enrolled
Drug / intervention
Gabapentin +1 moredrug
Likely dose
Gabapentin 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Oral Gabapentin Versus Placebo for Treatment of Postoperative Pain Following Photorefractive Keratectomy: A Randomized, Double-masked, Single Center, Placebo-controlled Clinical Trial
In Brief
A clinical study evaluating Gabapentin and placebo for Postoperative Pain. Completed, enrolled 106 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the effectiveness of an oral medication called gabapentin in reducing pain after Photorefractive Keratectomy (PRK) eye surgery and to assess the frequency of use of rescue medication interventions, defined as non-steroidal anti-inflammatory (NSAID) eye drops and oral narcotic medication.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostoperative Pain
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2008
First PostedNov 2008
Primary CompletionJul 2009
TodayJul 2026
First PostedNov 19, 2008
Enrollment StartJul 1, 2008
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 17.6 years ago
Interventions
Gabapentindrug
Gabapentin 300 mg taken by mouth thrice daily for 7 days
placebodrug
placebo (sugar pill) taken by mouth thrice daily for 7 days